Palisade Capital Management’s Pacira BioSciences PCRX Stock Holding History

Palisade Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6,500	Closed	-$219K	–	575
2016 Q2	$219K	Buy	6,500 +2,250	+53%	+$111K	0.01%	514
2016 Q1	$225K	Buy	4,250 +1,250	+42%	+$73.1K	0.01%	515
2015 Q4	$230K	Sell	3,000 -4,500	-60%	-$255K	0.01%	511
2015 Q3	$308K	Buy	7,500 +2,000	+36%	+$123K	0.01%	492
2015 Q2	$389K	Buy	5,500 +1,250	+29%	+$98.4K	0.01%	485
2015 Q1	$378K	Buy	+4,250	New	+$431K	0.01%	468

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Palisade Capital Management's PCRX Position: Q3 2016 in Review

Palisade Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 6,500 shares — an estimated $219K sold.

Palisade Capital Management first reported a position in PCRX in Q1 2015 and held it in 6 quarters. The position peaked at $389K in Q2 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

Palisade Capital Management reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
Palisade Capital Management sold 6,500 Pacira BioSciences shares in Q3 2016, an estimated $219K.
Palisade Capital Management first reported a position in Pacira BioSciences in Q1 2015 and held it in 6 quarters.
Palisade Capital Management's Pacira BioSciences position peaked at $389K in Q2 2015.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Palisade Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.